Transcoronary concentration gradient of sCD40L and hsCRP in patients with coronary heart disease

被引:37
作者
Wang, Ying
Li, Li
Tan, Hong-Wei
Yu, Guang-Sheng
Ma, Zhi-Yong
Zhao, Yu Xia
Zhang, Yun
机构
[1] Shandong Univ, Dept Cardiol, QiLu Hosp,Chinese Minist Educ, Key lab Cardiovasc Remodeling & Funct Res, Jinan 250012, Peoples R China
[2] Shandong Univ, Dept Cardiol, QiLu Hosp, Chinese Minist Hlth, Jinan 250012, Peoples R China
[3] Shandong Provincial Hosp, Jinan 250021, Peoples R China
关键词
soluble CD40 ligand; HsC-reactive protein; coronary disease; inflammation;
D O I
10.1002/clc.26
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recent studies indicated that local inflammation played a pivotal role in the pathogenesis of coronary heart disease. Soluble CD40 ligand (sCD40L) and hsC-reactive protein (hsCRP) are important inflammatory mediators. However, whether they can reflect local coronary inflammation is unclear. Hypothesis: We hypothesized that transcoronary concentration gradient of sCD40L could reflect local inflammation in patients with coronary heart disease (CHD) more reliably. Methods: Forty subjects were divided into unstable angina pectoris (UAP) group (n = 20), stable angina pectoris (SAP) group (n = 10), and controls (n = 10). Blood samples were collected from the coronary sinus (CS), aortic root (AO), and femoral vein (FV). The coronary circulation was expressed as CS-AO difference, while system circulation was expressed as FV-AO difference. sCD40L and hs-CRP were measured. Results: Complex lesions were more frequent in the UAP group than in the SAP group (85% vs. 40%, p < 0.05). CS-AO differences of sCD40L were much greater in the UAP group than in the SAP or control groups, and were greatly higher than FV-AO difference in UAP group (465.49 +/- 247.85 pg/mL vs. -14.94 +/- 83.41 pg/mL; 465.49 +/- 247.85 pg/mL vs. -7.66 +/- 78.54 pg/mL; 465.49 +/- 247.85 pg/mL vs. -7.99 +/- 141.34 pg/mL, all p < 0.001). CS-AO differences of sCD40L were higher in patients with complex lesions than with smooth lesions (657.86 +/- 384.76 pg/mL vs. 317.62 +/- 409.98 pg/mL, p < 0.01). There were no significant differences of CS-AO in hs-CRP among the three groups. Conclusions: In patients with CHD, the transcoronary concentration gradient of sCD40L is more sensitive than hsCRP, and sCD40L possibly a better marker of local inflammtion and plaque instability.
引用
收藏
页码:86 / 91
页数:6
相关论文
共 17 条
[1]   CORONARY ANGIOGRAPHIC MORPHOLOGY IN MYOCARDIAL-INFARCTION - A LINK BETWEEN THE PATHOGENESIS OF UNSTABLE ANGINA AND MYOCARDIAL-INFARCTION [J].
AMBROSE, JA ;
WINTERS, SL ;
ARORA, RR ;
HAFT, JI ;
GOLDSTEIN, J ;
RENTROP, KP ;
GORLIN, R ;
FUSTER, V .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1985, 6 (06) :1233-1238
[2]   Platelet-derived CD40L -: The switch-hitting player of cardiovascular disease [J].
André, P ;
Nannizzi-Alaimo, L ;
Prasad, SK ;
Phillips, DR .
CIRCULATION, 2002, 106 (08) :896-899
[3]   Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina -: Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes [J].
Aukrust, P ;
Müller, F ;
Ueland, T ;
Berget, T ;
Aaser, E ;
Brunsvig, A ;
Solum, NO ;
Forfang, K ;
Froland, SS ;
Gullestad, L .
CIRCULATION, 1999, 100 (06) :614-620
[4]   DIFFERENTIAL PROGRESSION OF COMPLEX AND SMOOTH STENOSES WITHIN THE SAME CORONARY TREE IN MEN WITH STABLE CORONARY-ARTERY DISEASE [J].
CHESTER, MR ;
CHEN, LJ ;
TOUSOULIS, D ;
POLONIECKI, J ;
KASKI, JC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 25 (04) :837-842
[5]   Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia effects of statin therapy [J].
Cipollone, F ;
Mezzetti, A ;
Porreca, E ;
Di Febbo, C ;
Nutini, M ;
Fazia, M ;
Falco, A ;
Cuccurullo, F ;
Davì, G .
CIRCULATION, 2002, 106 (04) :399-402
[6]   Possible role of brain-derived neurotrophic factor in the pathogenesis of coronary artery disease [J].
Ejiri, J ;
Inoue, N ;
Kobayashi, S ;
Shiraki, R ;
Otsui, K ;
Honjo, T ;
Takahashi, M ;
Ohashi, Y ;
Ichikawa, S ;
Terashima, M ;
Mori, T ;
Awano, K ;
Shinke, T ;
Shite, J ;
Hirata, K ;
Yokozaki, H ;
Kawashima, S ;
Yokoyama, M .
CIRCULATION, 2005, 112 (14) :2114-2120
[7]   Soluble CD40 ligand in acute coronary syndromes [J].
Heeschen, C ;
Dimmeler, S ;
Hamm, CW ;
van den Brand, MJ ;
Boersma, E ;
Zeiher, AM ;
Simoons, ML ;
CAPTURE Study Investigators .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (12) :1104-1111
[8]   Local release of C-reactive protein from vulnerable plaque or coronary arterial wall in injured by stenting [J].
Inoue, T ;
Kato, T ;
Uchida, T ;
Sakuma, M ;
Nakajima, A ;
Shibazaki, M ;
Imoto, Y ;
Saito, M ;
Hashimoto, S ;
Hikichi, Y ;
Node, K .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (02) :239-245
[9]   Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study [J].
Kinlay, S ;
Schwartz, GG ;
Olsson, AG ;
Rifai, N ;
Sasiela, WJ ;
Szarek, M ;
Ganz, P ;
Libby, P .
CIRCULATION, 2004, 110 (04) :386-391
[10]   CD40-CD40L interactions in atherosclerosis [J].
Lutgens, E ;
Daemen, MJAP .
TRENDS IN CARDIOVASCULAR MEDICINE, 2002, 12 (01) :27-32